Protecting Reproductive Freedom Act

Bill: 117-hr-8976
Sponsor: full_name: Rep. Ryan, Patrick [D-NY-19]
Introduced: 2022-09-22
Policy area: Health
Latest action: action_date: 2022-09-23
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-09-22
action_desc: Introduced in House
text: <p><b>Protecting Reproductive Freedom Act</b></p> <p>This bill prohibits states from restricting mifepristone or misoprostol that is approved for medical abortion from being sent across state lines or from being prescribed by telehealth. States are also prohibited from establishing in-person dispensing requirements.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 8976 IN THE HOUSE OF REPRESENTATIVES September 22, 2022 Mr. Ryan of New York introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To preempt State restrictions on dispensing mifepristone or misoprostol, and for other purposes.

1. Short title This Act may be cited as the Protecting Reproductive Freedom Act . 2. Preemption of State restrictions on dispensing mifepristone and misoprostol No State may establish, implement, or enforce— (1) any prohibition or restriction on shipping or sending mifepristone or misoprostol across State lines; (2) any requirement that mifepristone or misoprostol be dispensed by a health care practitioner in person; or (3) any prohibition or restriction on prescribing or dispensing mifepristone or misoprostol by means of telehealth. 3. Report Not later than 30 days after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Congress on ways to expand access to abortion medication. 4. Definitions In this Act: (1) The term mifepristone means mifepristone that is— (A) approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); (B) indicated for medical abortion; and (C) subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ). (2) The term misoprostol means misoprostol that is— (A) approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); (B) indicated for medical abortion; and (C) subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ).